Answers are grounded in this paper and cite their sources.
Mendelian randomization study reveals potential genetic factors in diabetic nephropathy, suggesting new therapeutic options.
. IRF2 was identified as a potential key transcription regulator. Drug predictions suggested calycosin, nitrofural, and nobiletin could target PEBP1, GNAI2, and KIF11, respectively. This SMR study suggested the causal role of circadian rhythm dysfunction in DN. Future research should focus on identifying specific genetic drivers, and exploring therapeutic strategies targeting circadian pathways to mitigate DN progression.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: